A. Daud

发表

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Manish R. Patel, Charles J. Vaske, Joe Y. Chang, 2016, Journal for Immunotherapy of Cancer.

Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials.

D. Schadendorf, P. Ascierto, R. Dummer, 2020, JAMA oncology.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016 .

Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program

F. Hodi, H. Kluger, M. Postow, 2017, Journal of immunotherapy.

Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006

J. Wolchok, A. Ribas, F. Hodi, 2021, European journal of cancer.

[Breast cancer in the early stage].

R. J. Jones, M. Espié, G. Giaccone, 2012, Gan no rinsho. Japan journal of cancer clinics.

Trials in progress: A phase 1, open-label, dose-escalation, pharmacokinetic, safety and tolerability study of the selective TAM kinase inhibitor PF-07265807 in patients with advanced or metastatic solid tumors.

S. Ou, J. Abbruzzese, V. Subbiah, 2021 .

An analysis of genetic heterogeneity in untreated cancers

Johannes G. Reiter, Jeffrey M. Gerold, K. Kinzler, 2019, Nature Reviews Cancer.

Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma.

R. Plummer, V. Giranda, P. Friedlander, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

J. Wolchok, A. Ribas, F. Hodi, 2018, Clinical Cancer Research.

Characteristics of pyrexia in BRAF V 600 E / K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I / II clinical trial

K. Flaherty, J. Sosman, J. Infante, 2015 .

Final overall survival for KEYNOTE-002: pembrolizumab (pembro) versus investigator-choice chemotherapy (chemo) for ipilimumab (ipi)-refractory melanoma

D. Schadendorf, P. Ascierto, R. Dummer, 2016 .

Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006

A. Ribas, F. Hodi, J. Schachter, 2018, British Journal of Cancer.

A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma

D. Schadendorf, P. Ascierto, R. Dummer, 2015, Journal of Translational Medicine.

Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy

R. Dummer, O. Hamid, M. Levesque, 2017, British Journal of Cancer.

Abstract 4217: Tumor mutational burden (TMB), T cell-inflamed gene expression profile (GEP) and PD-L1 are independently associated with response to pembrolizumab (Pembro) in patients with advanced melanoma in the KEYNOTE (KN)-006 study

J. Lunceford, Chunsheng Zhang, J. Larkin, 2019, Prevention, Early Detection, and Interception.

950 Final analysis: phase 1b study investigating intratumoral injection of toll-like receptor 9 agonist vidutolimod ± pembrolizumab in patients with PD-1 blockade–refractory melanoma

D. Davar, J. Kirkwood, A. Ribas, 2021, Journal for ImmunoTherapy of Cancer.

Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study

D. Schadendorf, C. Dooms, P. Ascierto, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Extended follow-up results of phase Ib study (BRIM7) of vemurafenib (VEM) with cobimetinib (COBI) in BRAF-mutant melanoma.

A. Ribas, I. Puzanov, A. Pavlick, 2015 .

New drugs in gynecologic cancer

P. Munster, D. Spriggs, A. Daud, 2001, Current treatment options in oncology.

Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001

J. Wolchok, H. Zarour, N. Ibrahim, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial.

K. Flaherty, J. Sosman, J. Infante, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase IB Study of Vemurafenib in Combination with the Mek Inhibitor, GDC-0973, in Patients (PTS) with Unresectable or Metastatic BRAFV600 Mutated Melanoma (BRIM7)

A. Ribas, I. Puzanov, A. Pavlick, 2012 .

SWOG S1320: A randomized phase II trial of intermittent versus continuous dosing of dabrafenib and trametinib in BRAFV600E/k mutant melanoma.

J. Kirkwood, A. Ribas, J. Moon, 2015 .

140 Relationship between programmed death ligand 1 (PD-L1) expression and clinical outcome in patients (pts) with melanoma (MEL) treated with pembrolizumab (pembro; MK-3475)

J. Lunceford, J. Wolchok, H. Zarour, 2014 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016 .

Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

J. Wolchok, A. Ribas, F. Hodi, 2018, Clinical Cancer Research.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Charles J. Vaske, Joe Y. Chang, Scott R. Presnell, 2016, Journal for ImmunoTherapy of Cancer.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, David M. Schauder, 2016, Journal for ImmunoTherapy of Cancer.

Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy

R. Dummer, A. Daud, O. Hamid, 2017, British Journal of Cancer.